Exhibit 99.1 Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update • Phase 1 data for CRB-701 (SYS6002) to be presented at ASCO Annual Meeting on June 1, 2024 • $116M of capital raised in Q1 2024 extending cash runway through Q1 2027 • Appointed Dr. Dominic Smethurst as Chief Medical Officer Norwood, MA, May 7, 2024 (GLOBE NEWSWIRE) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified p ...